测量SARS-CoV-2特异性T细胞反应的潜在临床效用
本文综述了T细胞免疫在COVID-19自然感染和疫苗接种中的作用,并借鉴结核病IGRA经验,探讨测量SARS-CoV-2特异性T细胞反应的潜在临床价值。T细胞反应出现早于抗体,与疾病严重程度和预后相关,疫苗可诱导稳健T细胞反应,但长期数据有限。基于SARS-CoV-2抗原的IGRA可区分康复者与未感染献血者。
要点
- T细胞反应在COVID-19病程中早于抗体出现,并与结局相关。
- CD4+和CD8+T细胞计数降低提示病情更重、病毒RNA阳性时间更长和死亡率更高。
- SARS-CoV-2疫苗诱导稳健T细胞反应,但长期T细胞反应数据有限。
核心结论
- 测量T细胞反应的数量和功能可能有助于COVID-19预后判断、疫苗免疫监测及人群免疫评估。
研究设计与样本
- 综述,检索PubMed截至2021年4月16日的文献。
主要发现
- T细胞反应在COVID-19早期即可检测到,早于抗体反应,并与COVID-19结局相关。
- 较低的CD4+和CD8+T细胞计数是更严重疾病、更长病毒RNA阳性持续时间和更高死亡率的标志。
- SARS-CoV-2疫苗接种可刺激稳健的T细胞反应,可能对保护起重要作用,但长期T细胞反应数据目前有限。
- 基于SARS-CoV-2抗原的IGRA可区分康复者和未感染的健康献血者。
关键数值与推荐
- 已开发多种检测SARS-CoV-2特异性T细胞反应的方法,包括IGRA、细胞内细胞因子染色和活化诱导标志物。
临床怎么用
- 简单检测T细胞反应的数量和功能可能用于COVID-19预后判断、监测SARS-CoV-2疫苗接种的免疫反应以及评估人群对关注变异株的免疫。
局限性
- 长期T细胞反应数据目前有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more information is still needed. OBJECTIVES: To provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB). SOURCES: PubMed articles up to 16 April 2021. CONTENT: T-cell responses can be detected very early in the course of COVID-19, earlier than the detection of antibody responses, and are correlated with COVID-19 outcome. Lower CD4+ and CD8+ T-cell counts are markers of more severe disease, longer duration of viral RNA positivity and increased mortality. In line with natural infection, SARS-CoV-2 vaccination stimulates robust T-cell responses, which probably play an important role in protection; data on long-term T-cell responses are currently limited. The utility of measuring T-cell responses is already well established in both aiding the diagnosis of TB infection using IGRAs, and evaluation of T-cell responses to TB vaccine candidates. A variety of assays have already been developed to measure SARS-CoV-2-specific T-cell responses, including IGRAs, intracellular cytokine staining and activation-induced markers. IGRAs based on SARS-CoV-2 antigens can distinguish between convalescent and uninfected healthy blood donors. IMPLICATIONS: Simple assays for measuring the quantity and function of T-cell responses may have utility in the prognostication of COVID-19, and for monitoring immune responses to SARS-CoV-2 vaccination and population-based immunity to SARS-CoV-2 variants of interest.
引用
- Goletti D, Petrone L, Manissero D, et al. The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. Clin Microbiol Infect. 2021. PMID: 34256141. doi:10.1016/j.cmi.2021.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。